A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (NCT07702578)
A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The study will compare TSC-101 plus standard of care (SOC) versus SOC alone in participants undergoing allogeneic peripheral blood stem cell transplantation from haploidentical or mismatched unrelated donors.
Who can join: Review the eligibility criteria below.
Location: Banner Health - MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Banner Health - MD Anderson Cancer Center — Gilbert, Arizona
- Honor Health Cancer Transplant Institute — Scottsdale, Arizona
- City of Hope — Duarte, California
- Stanford - School of Medicine — Stanford, California
- University of Colorado - Anschutz Cancer Center — Aurora, Colorado
- SCRI - Colorado Blood Cancer Institute — Denver, Colorado
- Yale — New Haven, Connecticut
- Memorial Cancer Institute — Hollywood, Florida
- Moffitt Cancer Institute — Tampa, Florida
- Northside Hospital — Atlanta, Georgia
- University of Chicago — Chicago, Illinois
- The University of Kansas Cancer Center — Kansas City, Kansas
- Johns Hopkins University — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute - Hematology/Oncology — Boston, Massachusetts
- Karmanos Cancer Institute — Detroit, Michigan
- Hackensack University Medical Center — Hackensack, New Jersey
- Mount Sinai Hospital — New York, New York
- Columbia University - Irving Medical Center — New York, New York
- The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
- Sarah Cannon Research Institute - TriStar Bone Marrow Transplant (BMT) — Nashville, Tennessee
- St. David's South Austin Medical Center — Austin, Texas
- Baylor University Medical Center — Dallas, Texas
- The University of Texas - MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (857) 399-9887
Email: mmotta@tscan.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in AML
- ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial — Houston, Texas
- A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant — Rochester, New York
- A Long Term Follow-up Study of TScan TCR-T Products — Duarte, California
- CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) — Sacramento, California
- Cardioprotection in AML — Charlottesville, Virginia
- UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy — Birmingham, Alabama
Explore by condition: All AML clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.